Dermatology

Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22nd 2025

By Skylar Jeremias

Article

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.

Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets

April 14th 2025

By Skylar Jeremias

Article

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.

Early Success of Adalimumab Biosimilars Featured at AMCP 2025

April 5th 2025

By Skylar Jeremias

Article

High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).

Adalimumab Biosimilars Show Similar Outcomes in Psoriasis After Nonmedical Switch

March 26th 2025

By Skylar Jeremias

Article

Switching between adalimumab products does not affect drug effectiveness or treatment duration in patients who have psoriasis, according to a Danish study.

Smart Tendering Policies Unlock Greater Biosimilar Savings

March 20th 2025

By Skylar Jeremias

Article

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.

Multiple Switches Between Adalimumab Biosimilar GP2017 and Humira for Psoriasis Maintain Biosimilarity

March 20th 2025

By Cameron Santoro

Article

Patients with moderate to severe plaque psoriasis who switched between the adalimumab biosimilar GP2017 and reference adalimumab did not impact immunogenicity, safety, or efficacy following up to 4 switches between both drugs.

Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD

March 18th 2025

By Skylar Jeremias

Article

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.

More Ustekinumab Biosimilars Join US Market Share Fight

March 13th 2025

By Skylar Jeremias

Article

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 others that launched earlier this year.

Pharmacists Play a Crucial Role in Adalimumab Biosimilars for Patient Care

March 5th 2025

By Kennedy Ferruggia

Article

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.

Psoriasis Biosimilars Saved VA $67 Million in 2023

February 12th 2025

By Skylar Jeremias

Article

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high costs of biologic therapies to treat chronic disease.